EUCTR2007-002142-37-DE进行中（未招募）1 期
SUTENT (SUNITINIB, SU11248) in Patients with Recurrent or Progressive Glioblastoma multiformeAn Academic Prospective Single-arm Phase II Clinical Trial including Translational Research Studies - SUTENT in Patients with Glioblastoma multiforme
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •[1]Patients present with a first recurrence or first progression of a histological confirmed primary supratentorial glioblastoma multiforme WHO Grade IV (Classification following WHO criteria).
- •Note: Patients may be entered based on local pathology from the original diagnostic tumor specimen. For Translational Research Studies the original paraffin block - including sufficient tissue of the primary tumor - is required. Stereotactic biopsies or open biopsies of the primary GBM without sufficient tumor tissue are not feasible and the patients must not be enrolled in this study.
- •[2]Patients with surgical resection of first tumor progression: Following standard therapy patients must have evidence of first tumor progression. In general, patients may have undergone prior surgical resection of the first tumor progression and will be eligible if the following conditions apply:
- •?Patients must have recovered from the effects of surgery
- •?To adequately asses the GBM before surgery and the extent of residual disease postoperatively, two MRIs scans have to be performed:
- •The first MRI scan within 2 weeks before surgery to document a progressed or recurrent GBM
- •The second MRI scan within 48 hours after surgery
- •Note: Patients must be on a steroid dosage that has been stable for at least 5 days before MRI. If the 48-hour scan is performed more than 14 days prior to study enrollment, the scan needs to be repeated (third MRI scan), however, the <48 hour MRI is the baseline scan.
- •Patients without surgical resection of first tumor progression: Patients must have evidence of first tumor progression following standard therapy as measured by a baseline MRI within 2 weeks prior to study enrollment (Macdonald criteria: e.g. tumor growth > 25% or new lesion).
- •Note: Patients must be on a steroid dosage that has been stable for at least 5 days before MRI. If the steroid dose has increased between the date of imaging and enrollment, a new baseline MRI is required on a stable steroid dosage of at least 5 days duration.
- •[3]Resolution of all acute toxic effects of prior therapy to grade = 1 (except alopecia, see Protocol Attachment A.5)
- •[4]Patients must have an ECOG performance status of 0-2 (refer to Protocol Attachment A.4)
- •[5]Patients must be = 18 years and = 75 years of age, with a life expectancy of greater than 8 weeks
- •[6]Patients must have adequate organ function as defined by the following criteria:
- •Bone Marrow Reserve-Platelets = 75.000/µL
- •-Absolute Neutrophil Count (ANC) = 1500/µL
- •-Hemoglobin = 10.0 g/dL
- •Blood Coagulation-aPTT = 1.5 times upper limit of normal (ULN)
- •Hepatic Function -ASAT and ALAT = 1.5 times ULN
- •-ALP = 2.5 times ULN
- •-Total Serum Bilirubin < 1 times ULN
- •Renal Function-Serum Creatinine = 1.5 times ULN
- •Metabolism-Serum Albumin = 3.0 g/dL
- •Heart Function-Left Ventricular Ejection Fraction (LVEF) = 50% as measured by transthoracic echocardiogram (ECHO)
- •All tests must be performed = 3 days prior to study enrollment. Eligibility for hemoglobin count may be reached by transfusion
- •[7]Signed and dated informed consent document by the patient, indicating that the patient has been informed of all the pertinent aspects of the trial prior to study enrollment
- •[8]Willingness and ability of the patient to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjec
排除标准
- •[9]The patient is active participant in another clinical trial.
- •[10]Exclusion of patients in the event of
- •?surgery for recurrence/progression within 1 week prior to study enrollment
- •?chemotherapy within 4 weeks prior to study enrollment
- •?treatment with more than one chemotherapy regime
- •?radiation therapy within 8 weeks to study enrollment
- •?evidence in baseline MRI of intratumoral or peritumoral hemorrhage deemed clinically significant by the treating physician (area of hemorrhage > 25% of tumor area)
- •?custody due to authorization by court or responsible authority.
- •[11]Significant Co-Morbidities within 12 months prior to study enrollment
- •?myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure
- •?pulmonary embolus
- •?cerebro-vascular accident including TIA (transient ischemic attack)
- •[12]Significant Co-Morbidities at Baseline Evaluation
- •?Clinically significant ongoing cardiac dysrhythmias of grade = 2, atrial fibrillation of any grade, QTc interval > 470 ms measured by electrocardiogram (ECG)
- •?Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy)
- •?A known HIV (human immunodeficiency virus) or Hepatitis B/C infection or severe acute infection
- •[13]Anticoagulation: Current treatment with therapeutic doses of Marcoumar / Sintrom excluding thrombosis prophylaxis with low dose Heparin.
- •[14]Antiepileptic Drugs: Concurrent use of EIADs within 2 weeks of study enrollment (patients must discontinue EIAD treatment = 14 days prior to study enrollment, refer to Section 4.2.2.2 and Protocol Attachment A.9)
- •[15]Pregnancy, Breastfeeding and Non-Contraception
- •?Female patients who are pregnant or nursing
- •?Patients who are sexually active and unwilling or unable to use a medically acceptable method of contraception during the trial.
- •Note: Female and male patients with reproductive potential have to use an approved contraceptive method (e.g., hormonal contraception, intrauterine device, condom with spermicide, etc.) during and for 3 months after discontinuation of study treatment. Female Patients with child-bearing age must have a negative serum pregnancy test = 3 days prior to study enrollment. During study treatment pregnancy has to be excluded (serum pregnancy tests every 2 weeks until tumor progression).
- •[16]Evidence of increased intracranial pressure
- •?midline shift > 5 mm
- •?distinct nausea and vomiting
- •[17]Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart excess risk associated with study participation or study drug administration, or which would make the patient inappropriate for entry into this study. The decision to enroll the patient in this study is in the judgment of the investigator.
- •[18]Hypersensitivity to sunitinibmalate or any other ingredients of SUTENT
研究者
相似试验
进行中（未招募）
不适用
SUNITINIB (SUTENT, SU11248) in Patients with Recurrent or Progressive Glioblastoma multiformeAn Academic Prospective Single-arm Phase II Clinical Trial including Translational Research Studies - Sunitinib in Patients with Glioblastoma multiformeGlioblastoma multiforme - WHO grade IV First progression/recurrenceMedDRA version: 9.1Level: LLTClassification code 10018337Term: Glioblastoma multiformeEUCTR2007-002142-37-ATMedizinische Universität Innsbruck70
Unknown
2 期
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma MultiformeGlioblastoma MultiformeNCT00535379Medical University Innsbruck70
进行中（未招募）
不适用
CONTINUOUS TREATMENT WITH SUNITINIB IN PATIENTS WITH SYMPTOMATIC PLEURAL AND/OR PERITONEAL MALIGNANT EFFUSIONS. - SUPPERSymtomatic malignant pleural and/ or peritoneal effusions regardless of the primary tumor site or histological charestisticsEUCTR2007-006459-38-BESt Augustinus50
进行中（未招募）
1 期
Phase II study of sunitinib malate (SUTENT®) in relapsed germ cell tumors in males.germ cell tumorEUCTR2007-004981-42-SKarodny onkologicky ustav28
进行中（未招募）
1 期
pfront Sunitinib (SU011248)® therapy followed by surgery in patients with metastatic renal cancer: a pilot Phase II study [SuMR] - SuMRThe current standard treatment in patients with metastatic renal cancer includes nephrectomy followed by immune therapy with either interleukin 2 (rIL-2) or interferon (IFN-a). Unfortunately, responses occur in only approximately 15% of patients, with less than 5% benefiting from a durable remission. Treatment options for patients who progress on this treatment remain very limited.MedDRA version: 9.1Level: LLTClassification code 10050018Term: Renal cancer metastaticEUCTR2006-004511-21-GBQueen Mary University London40